Analyst Information
Joseph Catanzaro, PhDSr. Research Analyst![]() Joe Catanzaro is a director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in 2018, Catanzaro spent four years at Cowen, where he also covered biotechnology. Before making the move to Wall Street, Catanzaro worked as a research scientist at Stony Brook University in New York. His work there focused on oncogene-mediated inflammatory signaling and resulted in multiple peer-reviewed publications. Catanzaro received his bachelor’s degree from Binghamton University in biological sciences and earned his Ph.D. in genetics from Stony Brook University. |
Universe Coverage: Healthcare: Biotechnology | |
ACHL | Achilles Therapeutics, Inc. |
AERI | Aerie Pharmaceuticals, Inc. |
AMAG | AMAG Pharmaceuticals, Inc. |
BMEA | Biomea Fusion, Inc. |
CRDF | Cardiff Oncology, Inc. |
CPRX | Catalyst Pharmaceuticals, Inc. |
CNTB | Connect Biopharma Holdings Ltd. |
CTMX | CytomX Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
EPIX | ESSA Pharma, Inc. |
GBT | Global Blood Therapeutics, Inc. |
GRCL | Gracell Biotechnologies Inc. |
HALO | Halozyme Therapeutics, Inc. |
HARP | Harpoon Therapeutics, Inc. |
IMAB | I-Mab |
IMGN | ImmunoGen, Inc. |
IOVA | Iovance Biotherapeutics, Inc. |
KROS | Keros Therapeutics, Inc. |
LPTX | Leap Therapeutics, Inc. |
MRKR | Marker Therapeutics, Inc. |
NK | NantKwest, Inc. |
NLTX | Neoleukin Therapeutics, Inc. |
NRIX | Nurix Therapeutics, Inc. |
OCUL | Ocular Therapeutix, Inc. |
OYST | Oyster Point Pharma, Inc. |
RAIN | Rain Therapeutics, Inc. |
RPTX | Repare Therapeutics Inc. |
SGEN | Seagen, Inc. |
SNSE | Sensei Biotherapeutics, Inc. |